RESUMO
Background: Preeclampsia is a common medical complication in pregnancy in developing countries. It is one of the most common causes that lead to maternal and fetal morbidity and mortality. Incidence of preeclampsia in world is 3-5%.1 In India preeclampsia complicates 5-15% of pregnancies. As a result of these changes serial alteration in lipid profile, mainly increase in serum triglycerides, cholesterol occurs in pregnant women.Methods: After IEC clearance and taking informed written consent from the patients, present study was conducted at the Department of Obstetrics and Gynaecology in PDZH, RNT Medical College, Udaipur from December 2020 to June 2022.Results: Study result based on 100 pregnant women with pre-eclampsia (BP >140/90 mm of Hg) as cases and 100 normotensive pregnant women (BP <140/90 mm of Hg) as controls. Cases had significantly higher total cholesterol (219.21±63.13 vs. 176.24±31.33, P<.0001), significantly higher triglycerides (mg/dL) (208.35±79.32 vs. 166.41±29.6, P<.0001), significantly higher LDL (mg/dL) (133.7±39.81 vs. 103.96±18.38, P<.0001), and significantly lower HDL (mg/dL) (43.29±7.09 vs. 50.18±8.15, P<.0001) in comparison to control.Conclusions: Women with pre-eclampsia had significantly higher serum Cholesterol, LDL, TG and significantly lower HDL in comparison to healthy pregnant women. There was a significant increase in the serum Cholesterol, LDL, TG in patients from mild to severe pre-eclampsia.
RESUMO
Background: No specific treatment is available for severe early-onset IUGR. To best of my knowledge, very few studies have assessed the potential benefit of Sildenafil therapy targeted to improve perinatal outcomes in pregnancies complicated by severe early-onset IUGR in Indian pregnant women.Methods: The present hospital based prospective study was carried out on one hundred ANC pregnant women with early and late fetal growth restriction and oligohydrominos at Pannadhai Mahila Chikatsalya, Rabindra Nath Tagore (RNT) Medical College, Udaipur, during Jan to Dec 2017. Sildenafil citrate 25 mg three times in a day was administered until delivery. Study subjects were subjected to fetal Doppler and ultrasound twice a week after the Sildenafil administration.Results: After sildenafil therapy, out of total 45 cases of IUGR alone, 39 cases (86.66 %) had improvement. Out of 35 cases of oligohydramnios alone, 28 cases (80 %) had improvement. Out of 20 cases having both IUGR and Oligohydramnios 16 had improvement (80 %) and only 4 cases did not show any improvement. Among gestation age 27-30 weeks group at the time of admission, there were total 10 cases out of which 5 (50 %) had early premature delivery (32-34 weeks), 3 (30 %) had late premature delivery (34-37 weeks) and 2 cases (2 %) had term delivery i.e. between 37-39 weeks after giving sildenafil treatment.Conclusions: The findings of the present study indicate that sildenafil citrate may offer a potential therapeutic strategy to improve outcomes in pregnant women facing foetal growth restriction and oligohydrominos.